Personalized Medicine Market to be Worth $922.72 Billion by 2030: Grand View Research, Inc.

SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- The global personalized medicine market size is expected to reach USD 922.72 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 6.95% from 2022 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.

Key Industry Insights & Findings from the report:

• The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe.
• The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing.
• North America dominated the market in 2021 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases.

Read 120 page full market research report for more Insights , "Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Nutrition & Wellness, Personalized Medicine Therapeutics), By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Personalized Medicine Market Growth & Trends

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Personalized Medicine Market Segmentation

Grand View Research has segmented the global personalized medicine market on the basis of product and region:

Personalized Medicine Market - Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Personalized Medicine Diagnostics
• Genetic Testing
• Direct-To-Consumer (DTC) Diagnostics
• Esoteric Lab Services
• Esoteric Lab Tests
• Personalized Medicine Therapeutics
• Pharmaceutical
• Genomic Medicine
• Medical Devices
• Personalized Medical Care
• Telemedicine
• Health Information Technology
• Personalized Nutrition & Wellness
• Retail Nutrition
• Complementary & Alternative Medicine

Personalized Medicine Market - Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Spain
• Italy
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players of Personalized Medicine Market

• GE Healthcare
• Illumina, Inc.
• ASURAGEN, INC.
• Abbott
• Dako A/S
• Exact Sciences Corporation
• Danaher Corporation (Cepheid, Inc.)
• Decode Genetics, Inc.
• QIAGEN
• Exagen Inc.
• Precision Biologics
• Celera Diagnostics LLC
• Biogen
• Genelex
• International Business Machines Corporation (IBM)
• Genentech, Inc.
• 23andMe, Inc.

Check out more related studies published by Grand View Research:

• Personalized Retail Nutrition And Wellness Market - The global personalized retail nutrition and wellness market size is expected to reach USD 3.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.9% from 2021 to 2028. The market growth can be attributed to the factors such as driving nutrition strategies, growing focus on nutrigenomics and nutrigenetics, a shift in the healthcare paradigm, and integration of data science for the development of innovative personalized nutrition.
• Regenerative Medicine Market - The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.
• Tumor Profiling Market - The global cancer/tumor profiling market size is expected to reach USD 21.08 billion by 2025, exhibiting a CAGR of 8.8%, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Browse through Grand View Research's  Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

SOURCE Grand View Research, Inc